glp 1 type 1 diabetes In patients with residual ß-cell function, GLP-1 treatment Weight-Loss Drug Use Has Risen

However, because the initial dose is low, some patients may notice the appetite suppression is strongest for the first four days and slightly wanes as they approach their next scheduled injection

doi: 10.1006/bbrc.2001.5648

Current research indicates that GLP-1RAs may offer therapeutic benefits beyond their established use in obesity and type 2 diabetes management

[DOI] [PMC free article] [PubMed] [Google Scholar] 37.Subramanian V, Rothenberg A, Gomez C, Cohen AW, Garcia A, Bhattacharyya S, et al

Cisplatin accumulates persistently in the mitochondria of energy metabolism-related organs (skeletal muscle, liver), forms platinum-mtDNA adducts to disrupt mitochondrial structure and function, and causes oxidative phosphorylation impairment and insufficient ATP production, ultimately driving persistent fatigue (Huot et al

Rafferty, A